Melina Rapoport

Melina Rapoport

Auto-generated profile, based on publicly available information

Melina Rapoport

Servicio Antimicrobianos, Departamento de Bacteriología, Instituto Nacional de Enfermedades Infecciosas-ANLIS 'Dr Carlos G. Malbrán', Av. Vélez Sarsfield 563 (C1282AFF), Ciudad Autónoma de Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
FPFernando pasteran
Fernando pasteran
DFDiego Francisco Faccone
Diego Francisco Faccone
APAlejandro Petroni
Alejandro Petroni
MRMelina Rapoport
Melina Rapoport
MGMarcelo Galas
Marcelo Galas
APAdriana Procopio
Adriana Procopio

17 February 2012 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
FPFernando pasteran
Fernando pasteran
CLCeleste Racelis Lucero
Celeste Racelis Lucero
MRMelina Rapoport
Melina Rapoport
LGLeonor Guerriero
Leonor Guerriero
IBIrene Barreiro
Irene Barreiro
ACAlejandra Corso
Alejandra Corso
Introduction: Tigecycline and intravenous (i.v.) fosfomycin could be alternative therapeutic options for the treatment of carbapenemase-possessing Enterobacteriaceae bacterial infections. However, routine laboratories are forced to test these drugs using minimum inhibitory concentration (MIC) methods as zone breakpoints are not available for the disc diffusion technique. Methodology: Clinical and Laboratory Standards Institute methods for agar dilution and disc diffusion were compared to determine tentative zone breakpoints that best correlate to tigecycline and i.v. fosfomycin MIC breakpoints defined by the European Committee on Antimicrobial Susceptibility Testing. A total of 195 Enterobacteriaceae with defined mechanisms of resistance were tested in duplicate assays. Half of the strains were characterized as carbapenemase producers (KPC-2, OXA-48, OXA-163, VIM-1, VIM-2, IMP-8, NDM-1). Results: Corresponding zone diameters of susceptible ≥15mm, resistant ≤12mm and susceptible ≥17mm, resistant ≤15mm for the 50µg fosfomycin plus 50µg glucose-6-phosphate and 200µg fosfomycin plus 50µg glucose-6-phosphate discs, respectively, allowed categorization of the strains with an acceptable level of error (< 10% minor errors, < 1.5 % major errors, < 1% very major errors and categorical agreement > 90%). For the 15µg tigecycline disc, the best performance was achieved with the corresponding zone diameters of susceptible ≥ 21mm and resistant ≤ 16mm, which eliminated the very major and major errors but not the minor errors (34.4%). Conclusions: Based on these results, tigecycline and fosfomycin can be included in the routine panel of antibiotics for susceptibility testing by disc diffusion to provide fast and reliable information for the selection of treatment alternatives, especially for strains with extreme resistance, as carbapenemase producers.

1 December 2014 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Closed access
EAEzequiel Albornoz
Ezequiel Albornoz
CLCeleste Lucero
Celeste Lucero
GRGenara Romero
Genara Romero
MRMelina Rapoport
Melina Rapoport
LGLeonor Guerriero
Leonor Guerriero
APAlejandro Petroni
Alejandro Petroni

1 January 2011 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
SONIA ALEJANDRA GOMEZSONIA ALEJANDRA GOMEZ
SONIA ALEJANDRA GOMEZ
MRMelina Rapoport
Melina Rapoport
ATAna Togneri
Ana Togneri
JVJosé Viegas-Caetano
José Viegas-Caetano
DFDiego Francisco Faccone
Diego Francisco Faccone
FPFernando pasteran
Fernando pasteran